Efficient cell culture system for hepatitis C virus genotype 6A
AssigneeHvidovre Hospital
InventorsJudith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
Life of this patent
Estimating the term…
Loading patent…
AssigneeHvidovre Hospital
InventorsJudith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
Estimating the term…
The present inventors developed hepatitis C virus 6a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a/2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a/2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analysis.
A nucleic acid molecule comprising a nucleic acid which encodes a recombinant human hepatitis C virus of genotype 6a/JFH1 that is capable of expressing said virus when transfected into cells, wherein said molecule encodes an amino acid sequence with a sequence identity of at least 95% to that of SEQ ID NO:
A nucleic acid molecule comprising a nucleic acid which encodes a recombinant human hepatitis C virus of genotype 6a/JFH1 that is capable of expressing said virus when transfected into cells, wherein said molecule encodes the amino acid sequence with a sequence identity of at least 95% to that of SEQ ID NO:
A method for producing a hepatitis C virus particle, comprising:
A hepatitis C virus particle comprising a nucleic acid molecule which encodes human hepatitis C virus of genotype 6a/JFH1 that is capable of expressing said virus when transfected into cells and wherein said nucleic acid molecule encodes the amino acid sequence with a sequence identity of at least 95% to that of SEQ ID NO:2, wherein said molecule encodes adaptive mutations F350S in the E1 protein and a T416A or a N417T in the E2 protein of SEQ ID NO:2, and wherein said adaptive mutation provides an improved ability to generate infectious viral particles in cell culture compared to an HCV genotype 6a/JFH1 virus without said adaptive mutations.
A hepatitis C virus particle, comprising a nucleic acid which encodes a recombinant human hepatitis C virus of genotype 6a/JFH1 that is capable of expressing said virus when transfected into cells and wherein said nucleic acid encodes the amino acid sequence with a sequence identity of at least 95% to that of SEQ ID NO 2, wherein said molecule comprises a T1389C adaptive mutation in the E1 gene and a T1581C, T1581G, or A1586G adaptive mutation in the E2 gene of SEQ ID NO:1, and wherein said adaptive mutations provide an improved ability to generate infectious viral particles in cell culture compared to an HCV genotype 6a/JFH1 virus without said adaptive mutations.
Dependencies are inferred from the claim text.